VEGFR-3 expression is correlated with tumor progression by means of lymphatic metastasis (in the case of breast, lung, ovarian, renal cell, colorectal, gastric, oral, cervical, prostate, pancreatic cancer and basal cell carcinoma) or angiogenesis (in the case of ovarian, colorectal, gastric, cervical, prostate, pancreatic, melanoma, laryngeal cancer).161 On the other hand, VEGFR-3 missense mutations are associated with different forms of autosomal dominant primary lymphedema,162 for example Milroy disease.163. This evidence concerns the gene FLT4 and basal cell carcinoma.